Study comparing SB35 biosimilar to Taltz in healthy adults
Treatments studied
This study compares a new biosimilar drug (SB35) to the approved drug Taltz in healthy volunteers. The purpose is to check how the body processes both drugs and if they are similar. Participation involves receiving injections and multiple health checks over several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 55 years old.
- You are generally healthy, with no significant medical conditions.
- Your weight is between 55 and 90 kg (about 121 to 198 lbs).
- You have not had a serious infection or live vaccine recently.
- You are not pregnant, planning to become pregnant, or nursing during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 study tests an experimental drug called TIX100 in healthy volunteers to check its safety and how the body processes it. The results will help determine if the drug can be studied in future trials for conditions like obesity or metabolic disorders.
This study tests a new biosimilar medicine (CKD-704) to see how it compares to the approved Skyrizi treatments for healthy adults. It checks how the medicine moves through the body, its safety, and how the immune system responds.
This study tests a new medicine (INCA033989) given as a shot or IV in healthy adults to see how the body processes it and if it's safe.
This trial studies how the drug risankizumab moves through your body after being given through a vein or under the skin. It helps doctors understand the best way to give the medicine to patients.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests a new drug, GenSci136, in healthy adults to see if it's safe and how the body processes it. If you qualify, you would receive the drug and be monitored for side effects.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.